These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17765511)

  • 1. Prevention of venous thromboembolism after acute ischaemic stroke.
    Ricci S; Celani MG; Righetti E; Dennis M; Sandercock P
    Lancet; 2007 Sep; 370(9589):735-6; author reply 736-7. PubMed ID: 17765511
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of venous thromboembolism after acute ischaemic stroke.
    Melero MJ; Bergroth B; Contardo DM; Mazzei MM
    Lancet; 2007 Sep; 370(9589):735; author reply 736-7. PubMed ID: 17765510
    [No Abstract]   [Full Text] [Related]  

  • 3. Thromboembolism prevention in ischaemic stroke.
    O'Donnell M; Kearon C
    Lancet; 2007 Apr; 369(9571):1413-1415. PubMed ID: 17467497
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of venous thromboembolism after acute ischaemic stroke.
    Martins HS; Scalabrini-Neto A; Velasco IT
    Lancet; 2007 Sep; 370(9589):736; author reply 736-7. PubMed ID: 17765513
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
    Levine M
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 8. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L; Boucher M
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG
    Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolism.
    Fitzmaurice D; Hobbs FD; McManus R
    Clin Evid; 2002 Jun; (7):199-213. PubMed ID: 12230644
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 12. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
    Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
    Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 14. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of catheter-related thrombosis in cancer patients.
    Prandoni P
    Lancet; 2009 Feb; 373(9663):523-4. PubMed ID: 19217973
    [No Abstract]   [Full Text] [Related]  

  • 16. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
    Schellong SM; Haas S; Greinacher A; Schwanebeck U; Sieder C; Abletshauser C; Bramlage P; Riess H
    Expert Opin Pharmacother; 2010 Dec; 11(18):2953-61. PubMed ID: 20950224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter 1: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Wille-Jorgensen P
    Br J Surg; 2006 Mar; 93(3):374; author reply 375-6. PubMed ID: 16498577
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Agnelli G; Bergqvist D; Dahl O; Eriksson B; Rud Lassen M; Mouret P; Rosencher N
    Br J Surg; 2006 Mar; 93(3):375; author reply 375-6. PubMed ID: 16498579
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
    Tangelder MJ; Bylock A; Held P
    Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
    [No Abstract]   [Full Text] [Related]  

  • 20. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine GJ; Lip GY
    Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.